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~ Increased nitrite in exhaled breath condensate (EBC) in patients 
with CF: a product of pharyngo-oral bacterial activity 
M. Johannesson 1 , H. Marteus 2, E. N~is 1 , R Kalm-Stephens 1 , S.L. Nordvall 1 , 
K. Alving 2. 1Dept of Woman and Child Health, Uppsala Universily, Uppsala; 
2 Dept of Physiology and Pharmacology, Karolinska Instituter, Stockholm, Sweden 
Introduction: Several studies have shown increased nitrite levels in F.BC in patients 
with CF, and this has been suggested to be the result of increased nitric oxide (NO) 
formation within the lower airways. However, we have previously shown that F.BC 
nitrite originates primarily in the pharyngo-oral tract in healthy subjects, and that 
it is a product of bacterial activity. 
Methods:  This study was performed in 15 patients with CF (10 43 years, 7 female) 
and 15 age-matched healthy control subjects. Exhaled NO (Niox, Aerocrine), and 
nitrite in saliva and F.BC (F.coScreen, J~iger) were measured before and 5 rain after 
a mouthwash with an antibacterial gent (chlorhexidine 0.2% for 30 s), a procedure 
which is known to reduce exhaled NO and nitrite levels in saliva and F.BC in healthy 
subjects. 
Results: At baseline, exhaled NO was lower in CF patients compared to controls 
(10.0±0.9 v. 13.4±1.7 ppb, p < 0.05; mean±SF.M). In contrast, F.BC nitrite was 
higher in CF patients (5.2±1.4 v. 2.5±1.1 gM, p<0.05).  Furthermore, salivary 
nitrite was increased in CF patients (347±88 v. 122±40 gM, p < 0.01), and there 
was good correlation between itrite levels in F.BC and saliva (r 0.65, p < 0.05). 
Chlorhexidine mouthwash further separated the exhaled NO levels in the two 
groups, indicating a partial masking of the reduced airway NO formation in CF 
by increased oral NO formation from nitrite. 
Conclusion: Our findings suggest hat increased F.BC nitrite in CF patients are 
related to salivary nitrite, thus indicating altered anaerobic bacterial activity in the 
pharyngo-oral tract in these patients. 
5. Immunology pulmonology 
~ Radiation dose estimation from thoracic CT scans in a 
CF population 
R. Chiron 1 , C. Maccia 2, F. Counil 1 , M. Saguintaah 3, C. Roudier 4, J. Donadieu 4. 
1 Centre de Ressources et compdtences pour la Mucoviscidose, Montpellier; 
2Centre d'Assurance de qualitd des Applications Technologiques clans le domaine 
de la Santd, Paris; 3 Radiopddiatrie, CHU Montpellier; 4 Institut de Veille Sanitaire, 
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At present, CF centres are using CT scans to monitor CF lung disease. Very few 
data are available on the effective dose calculation even though this is a key factor 
in assessing CT protocols, particularly in pediatric patients. 
Objective: To calculate the organ dose and the effective dose from thoracic 
CT scans in a CF population. 
Methods:  The dose calculation was based on ImpactScan software and used a 
phantom model age-corrected for children. Effective radiation doses per CT was 
calculated from protocol information and radiation measurement in 42 typical 
CF patients followed in our centre and having thoracic CT before December 2004. 
Results: The average was 0.6 CT per year (0.1 1.9). Age at first CT was 6.5 years 
(0.2 35) with 3.8 years (0.2 21.2) follow-up. 3 patients died (3.8%) and the survival 
rate was 85.1% at 29 years old (o 10.4%). The cumulative organ doses from 
thoracic CTs at 5, 10 and 20 years were respectively 6.3, 9.7 and 15.4 for lungs; 
1.72, 2.68 and 4.36 for bone marrow; 1.41, 2.45 and 6.15 for kidneys and <1 mSv 
for liver, brain and gonadal tissues. The cumulative ffective dose (mSv) per patient 
was 7.7 at 5 years, 16.1 at 10 years, 27.6 and 23 at 30 years. 
Conclusion: In this CF population, effective doses from thoracic CT scans were 
moderate regarding environmental exposure and carcinologic risk. The radiation 
dose from thoracic CTs performed with new radiological protocols that use 1 mSv 
and protection regarding all tissues out of  the area of interest should be lower than 
in the past. 
• ISFDG-PET/CT contribution to the assessment of lesion severity in 
cystic fibrosis (CF) 
M. Klein 1 , S. Armoni 2, D. Shoseyov 2, M. Orevii 1 , R. Chisin 1 , E. Kerem 2. 1Nuclear 
Medicine, Hadassah University Hospital, 2Pediatrics, Hadassah University Hospital 
Mount Scopus, .Jerusalem, Israel 
Objeclives: Few non-invasive methods are available to monitor disease activity in 
CF. Chronic lung inflammation is complicated by bouts of superimposed infection. 
Our aim was to evaluate use of PET/CT for assessment of the severity of lung 
inflammation/infection n CF. 
Methods: PET/CT was performed for 15 patients (pts) (age: 14 54 yrs) followed in 
the CF clinic. SUV was measured in normal ung and disease burden was evaluated by 
calculating the mean value for the SUVmax (MSUV) of all lung foci. PET severity score 
(PSS) was based on the number of foci and their MSUV. PET/CT reading was blinded 
to clinical data. Correlative data included current FEV1 and sputum bacteriology. 
Results: According to PSS, pts were assigned to 4 groups: normal (grade 0), mild (1), 
moderate (2), severe (3). 
Table 1 PET Severity Score 
PET score N of foci MSUV N of patients 
0 0 0 1 
1 1 3 up to 1.6 5 
2 2 7 22.3 6 
3 7 9 2.032.91 3 
MSUVs of groups 1, 2 and 3 were 5, 7 and 10 times higher than SUV of normal 
lung background (0.3) respectively. Extensive PET abnormalities were correlated with 
atypical mycobacterium infection in all 3 pts of the severe group. In the 12 other pts, 
despite widespread CT findings (multiple bronchiectasies, infiltration, nodules, ground 
glass), there were relatively few foci of mild to moderately increased FDG uptake on 
PET. Furthermore, no correlation was found between PET and FEV 1. 
Conclusions: Our small series suggest he feasibility of using PET to assess lung 
inflammation i CF, using PSS based on MSUV and number of foci 
• Clinical usefulness of bronchoalveolar lavage (BAL) of patients 
with Cystic Fibrosis 
J. Dalberg 1'2, M. Skov 1 , K.G. Nielsen 1, T. Pressler 1. 1pulmonary Service 
and Cystic Fibrosis Centre, 2Dept. of Lungtransplantation, National University 
Hospital Rigshospitalet, Copenhagen, Denmark 
Aims: Children and adults with CF exhibiting clinical or respiratory deterioration 
despite routine treatment strategies. Patients who do not produce sputum reliably 
may be subject o an invasive procedure of BAL for more precise microbiological 
investigations. This study aimed to retrospectively evaluate the value of BAL as a 
supplementary diagnostic tool for exacerbation i CF lung disease. 
Methods:  30 files of CF-patients (14F/16 M, mean range 14 yrs, range 2 38) 
were reviewed in a retrospective study of all BAL-procedures performed uring 
the period from 2003 to 2005. 282 CF patients are followed on a regular monthly 
basis in outpatient clinic at our centre. Indications, clinical condition, lung function 
parameters, radiological findings and bacteriology were registered. 
Results: 36 BAL were performed in 30 patients with CE The indication were 
increased cough in 50%, declining lung function in 47% and increased sputum 
production in 30% of all cases. Microscopy of  BAL resulted in change of antibiotica 
regimen in 16% of the cases and results of culturing changed the treatment in 72% 
of cases. The result of  antibiotica resistance analysis changed treatment in 25% of 
all cases. No complication to BAL was registered. 
Conclusions: BAL is a safe procedure and contributes considerably to more specific 
diagnosis of reasons for pulmonary symptoms in CF and to changes in treatment 
regimens. Particularly, in the cases where symptoms continued in spite of antibiotic 
treatment, BAL seemed to be of overall importance to point out the relevant 
microbiological agents. 
